ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors [0.03%]
免疫检查点抑制剂、VEGF（R）抑制剂或多种靶向酪氨酸激酶抑制剂与放射治疗联合应用的安全性共识陈述（欧洲医学肿瘤学会和欧洲放射肿瘤学学会）
E S M van Aken,B Devnani,A Prelaj et al.
E S M van Aken et al.
Background: The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading...
A Temporal Paradox in the Proposed Risk-Adjusted Surveillance Algorithm for Metastatic Colorectal Cancer [0.03%]
一种用于转移性结直肠癌的风险调整型监测算法的时空悖论
Huichuan Tian,Rong-Xin Zhang,Deyao Zhang
Huichuan Tian
J-Y Blay,A Cervantes,F André et al.
J-Y Blay et al.
Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer [0.03%]
一线转移性结直肠癌的风险调整CT方案治疗
R Salazar,A Carmona-Bayonas
R Salazar
To conclude, this study provides a compelling, evidence-based foundation for risk-adjusted follow-up in mCRC, challenging outdated surveillance rhythms. It brings us closer to precision oncology-not in treatment selection this time, but in ...
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial [0.03%]
随机双盲3期CheckMate 9ER试验最终分析：纳武利尤单抗联合卡博替尼对比舒尼替尼治疗晚期肾细胞癌患者的疗效和安全性
R J Motzer,B Escudier,M Burotto et al.
R J Motzer et al.
Background: Nivolumab plus cabozantinib (NIVO+CABO) showed significant benefits over sunitinib (SUN) in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for previously untreated ad...
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer [0.03%]
结肠癌患者五年CT和CEA随访对生存结果的影响
C Lepage,J-M Phelip,L Cany et al.
C Lepage et al.
Background: Intensive follow-up of patients after curative surgery for colorectal cancer is recommended by various scientific societies. However, these recommendations are based mainly on expert opinions, while the result...
Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer [0.03%]
蒽环类药物在基因高危、淋巴结阴性、HR阳性/HER2阴性的乳腺癌中的影响
N Chen,J Q Freeman,S Yarlagadda et al.
N Chen et al.
Background: The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor-positive (HR+)/HER2...
Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 [0.03%]
一项随机III期试验：对根治性子宫切除术和淋巴结清扫术后中危、早期宫颈癌患者辅助放疗与放化疗进行对比——NRG肿瘤学/GOG-263/KGOG1008研究结果
S Y Ryu,W Deng,K Albuquerque et al.
S Y Ryu et al.
Background: To determine whether adjuvant chemoradiation (CRT) with weekly cisplatin improves recurrence-free survival (RFS) compared to radiation (RT) in pathologically proven intermediate risk early-stage cervical cance...